国产91视频久久,亚洲综合色图在线观看,五月天操逼网,日韩色色AV,青青在线A片,亚洲最大色在线观看,欧美熟妇丝袜诱惑,青青操逼视频,日韩无码操出水

 
Guideview > FDA
  • 2024 FDA Issued CRLs
    2024 FDA Issued CRLs FDA The FDA issued Complete Response Letters (CRLs) for multiple drug applications in 2024, citing concerns about efficacy, safety, and manufacturing. Learn about the rejected drugs, reasons behind CRLs, and their impact on pharmaceutical companies.
  • Will the FDA Conduct Large-Scale Layoffs?
    Will the FDA Conduct Large-Scale Layoffs? FDA Will the FDA Conduct Large-Scale Layoffs? Check out the voting results at LinkedIn or X (Twitter) now!
  • Trump's Presidency: Impact on the U.S. Biopharma Industry
    Trump's Presidency: Impact on the U.S. Biopharma Industry FDA Explore the implications of Trump's return on U.S. biopharma: healthcare cost reforms, IRA adjustments, reshoring manufacturing, and FDA/NIH shifts. Key focus areas for Chinese pharma include supply chain resilience and navigating new cross-border data regulations.
  • Drug RA | FDA: December 2024 Training: Innovative Therapies - Gene Therapy
    Drug RA | FDA: December 2024 Training: Innovative Therapies - Gene Therapy FDA The FDA's December 2024 Clinical Investigator Training Course focused on gene therapy, covering key stages in the development of cell and gene therapies. The session also introduced new initiatives to support rare disease treatments and improve regulatory processes.
  • Identification and Classification of Mutagenic Impurities from FDA Deficiency Letters
    Identification and Classification of Mutagenic Impurities from FDA Deficiency Letters FDA Explore the identification, classification, and control of mutagenic impurities in pharmaceuticals. Learn about ICH M7 guidance, QSAR evaluation, and FDA requirements for mutagenicity risk assessment in drug submissions.
  • FDA Official Departure Wave?
    FDA Official Departure Wave? FDA Dr. Patrizia Cavazzoni, FDA's CDER Director, announces her departure next week, following several senior FDA officials. The changes reflect shifts after Trump’s election and his nominations for top HHS and FDA roles.
  • 5 FDA Decisions to Watch in Q1 2025
    5 FDA Decisions to Watch in Q1 2025 FDA Discover the top 5 FDA decisions to watch in Q1 2025, including key drug approvals like Leqembi for Alzheimer's, Dato-DXd for breast cancer, and more groundbreaking treatments.
  • FDA 2025 Q1 Approval Overview (II)
    FDA 2025 Q1 Approval Overview (II) FDA Drug Approvals Explore the FDA 2025 Q1 approval overview, featuring groundbreaking treatments like Vimseltinib for TGCT, Mirdametinib for NF1-PN, and innovative therapies in oncology, immunology, and more.
  • FDA 2025 Q1 Approval Overview (I)
    FDA 2025 Q1 Approval Overview (I) FDA Drug Approvals The FDA's 2025 Q1 approval pipeline includes promising treatments for diabetes, cancer, and central nervous system disorders. Key candidates include Ozempic for kidney disease, Subvenite for epilepsy, and TX05, a HER2-targeted cancer biosimilar.
  • FDA Approvals Summary - December 2024
    FDA Approvals Summary - December 2024 FDA Drug Approvals The FDA approved several major drugs in December 2024, including treatments for Alzheimer's, cystic fibrosis, hemophilia, and cancer. This list highlights key drugs like Zepbound, Alyftrek, and Ensacove, marking significant advances in various therapeutic areas.
< Pre 12345678...10Next >
花莲县| 岳普湖县| 普兰县| 聂拉木县| 普定县| 九江县| 库尔勒市| 安阳市| 延吉市| 东乌| 钟山县| 柳林县| 湖南省| 尼勒克县| 武夷山市| 舟曲县| 萝北县| 阳山县| 高碑店市| 长沙市| 陕西省| 河间市| 武平县| 玉林市| 宽城| 永济市| 修武县| 盐源县| 清苑县| 沭阳县| 禹州市| 罗山县| 钦州市| 巫山县| 南部县| 平安县| 和硕县| 镇沅| 高雄市| 新营市| 天水市|